Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies.

A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs.

Merck's blockbuster cancer drug Keytruda generated $16.40 billion in first-half 2026 sales, up 4.2% year-over-year, with expectations for continued growth through 2028 when it reaches peak sales of $35 billion. However, the company faces significant headwinds as biosimilar competition is expected around 2028-2029, which will likely cause sharp sales declines. Merck stock has outperformed the industry year-to-date but currently holds a Zacks Rank #4 (Sell) rating.

Bristol Myers Squibb (BMY) has been a trending stock but faces headwinds with shares down 11.1% over the past month. While the company maintains a Zacks Rank #3 (Hold) rating and trades at a valuation discount to peers, earnings estimates have declined 3.6% over the last 30 days. The company has a strong track record of beating consensus estimates but faces modest revenue growth projections of 3.4% for the current fiscal year.

Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles.

BlackLine announced its 2026 Modern Accounting Awards, honoring six enterprise leaders—Booking Holdings, Bristol Myers Squibb, James Hardie, LAZ Parking, Payoneer, and US Foods—for redefining financial operations through unified data architectures, intelligent automation, and agentic workflows. These organizations have eliminated tens of thousands of manual close hours and established continuous, audit-ready financial operations.

Bristol Myers Squibb (BMY) closed down 2.58% to $57.60, underperforming the S&P 500. The company is set to report earnings on October 29, 2026, with projected EPS of $1.56 (down 4.29% YoY) and revenue of $12.54 billion (up 2.59% YoY). BMY trades at a Forward P/E of 8.7, below its industry average of 23.43, and holds a Zacks Rank #3 (Hold) rating with recent downward estimate revisions.

Bristol Myers Squibb (BMY) has outperformed the S&P 500 with a 35.8% gain over the past year, driven by strong performance from its Growth Portfolio including Opdivo Qvantig, Reblozyl, Camzyos, and Breyanzi. Recent FDA approvals like Zenbexus and positive pipeline progress offer long-term growth potential. However, the legacy portfolio faces continued generic competition, and much of the near-term optimism appears reflected in current valuations. Analysts recommend a cautious stance with a Hold rating.

The market currently exhibits conflicting signals with investors experiencing fear (CNN Fear & Greed Index at 38) while valuation metrics like the Buffett Indicator (237%) and Shiller CAPE ratio suggest greed. Buffett's contrarian investing rule advises being fearful of overvalued growth stocks while seeking greedy opportunities in undervalued sectors like energy and healthcare. Success requires balancing both extremes rather than acting on a single indicator.

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.

Bristol Myers Squibb (BMY) has demonstrated a strong track record of beating earnings estimates, with an average beat of 19.01% over the last two quarters. The company has a positive Earnings ESP of +1.12% and a Zacks Rank #2 (Buy) rating, suggesting another earnings beat is likely in its next report expected on October 29, 2026. Stocks with positive Earnings ESP and Zacks Rank #3 or better historically beat consensus estimates nearly 70% of the time.